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That Is the Predominant Transcript in Both Erythroid 
and Postcapillary Venule Endothelium 
By Sadahiko Iwamoto, Jianping Li, Toshinori Omi, Sigenori Ikemoto, and Eiji Kajii 
The Duffy gene has been shown not to be split by introns, 
even in its 5’ untranslated region, and to be expressed not 
only in erythroid but in postcapillary venule endothelium of 
almost every organ in the body. To further investigate the 
transcriptional start position in erythroid and postcapillary 
venule endothelium, we performed  5‘-rapid amplification of 
cDNA ends (5‘-RACE). While every positive clone of 5‘-RACE 
encoded  the  identical sequence  of  previously identified 
cDNA downstream from nucleotide 203,  the upstream se- 
quences  were  different. The  upstream sequences  corre- 
sponded to the sequence from nucleotide -279  to -3081 
-357  in erythroblasts and from -279  to -3551-383  in lung 
and were regarded as comprising a novel exon. This novel 
exon encoded seven residues initiated with a methionine, 
linked to nucleotide 203  in-frame and in agreement with 
the GT-AG splicing rule. The major erythroid transcriptional 
start position was identified in human erythroleukemia  cells 
HE DUFFY blood group system consists of  four major  T  phenotypes:  Fy(a+b-),  Fy(a-b+),  Fy(a+b+),  and 
Fy(a-b-).  Antisera  anti-Fya and  anti-Fyb define the  two 
principal antigens. The murine monoclonal antibody (MoAb) 
anti-Fy6 defines another Duffy antigenic determinant present 
in  all red  blood  cells  except  for those  of  the  Fy(a-b-) 
phenotype.’ MoAb anti-Fy6 precipitates a glycoprotein from 
Duffy-positive red blood cells, named glycoprotein D, of  35 
to 45 kD.*  The Duffy cDNA3 and its genomic DNA4.’ have 
been  cloned, and the  one-base substitution resulted in  an 
amino acid substitution at residue 44 that seemed to be re- 
sponsible for deciding the Fya/Fyb  alloantigen system. 
Fy(a-b-)  erythrocytes are resistant to  invasion by  the 
malarial parasites Plasmodium viva and P  knowlesi.  The 
receptors for parasite invasion of erythrocytes are related to 
the Duffy blood group antigen.6 This antigen has also been 
shown to function as a receptor for chemokines, including 
interleukin-8 (IL-8), melanoma growth-stimulating activity 
(MGSA),  monocyte  chemotactic  protein-1  (MCP-l), and 
regulated on  activation, normal  T  expressed and  secreted 
(RANTES), because these chemokines bind to Duffy-posi- 
tive but  not  to Duffy-negative  erythrocyte^.^  Furthermore, 
the recombinant Duffy protein expressed on K562 or human 
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by primer extension and in bone marrow by ribonuclease 
protection analysis at 34 bases upstream  from the first ATG 
codon.  Distinctively, in lung and kidney, the transcription 
was started at 82 bases upstream  from  the ATG. Both North- 
ern blotting and reverse transcription-polymerase  chain re- 
action followed by Southern analysis indicated a predomi- 
nance of the novel spliced form of mRNA  of about 50- to 
200-fold  comparing  with  the unspliced  form, in  every studied 
organ and erythroid lineage cells. The spliced form of cDNA 
has been transfected  into  a human erythroleukemic  cell line, 
K562, and the expressed protein reacted with Duffy-specific 
murine monoclonal antibody Fy6.  These  studies indicate 
that the product from the spliced form of mRNA is the major 
product of  the Duffy gene in the erythroid lineage and post- 
capillary venule endothelium. 
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embryonic kidney cells binds chemokines.*,’  It has been pos- 
tulated that the Duffy blood group antigen acts as a scavenger 
for chemokines. 
The Duffy protein has been shown to be expressed along 
postcapillary venules throughout the body, except for liver.’” 
On  RNA blot analysis, Duffy  cDNA identified mRNA in 
the bone marrow, kidney, spleen, heart, lung, muscle, duode- 
num, pancreas, fetal liver, placenta, and  The fetal 
brain mRNA was distinct from others (1.27 kb) for its tran- 
scriptional size, 8.5 kb and 2.2 kb. However, Southern blot- 
ting and fluorescence in situ hybridization analysis indicates 
that  the  Duffy  gene  (FY) is  a single-copy  gene.’.’’  Some 
genes produce erythroid and nonerythroid proteins by  alter- 
native use of tissue-specific promoter 
The genomic structure of  FY has been shown not  to be 
split by  introns, even in  its 5’ and 3’ untranslated regions 
(UTRS).~.~  The genes of IL-8 receptors, which are the highly 
homologous genes of FY, are not split by  introns within the 
coding regions but are split in the 5’  UTRs; iZ8ru is formed 
from two exons and iZ8rb is formed from 11 ex on^.'^^'^ From 
its broad organ distribution and the doubtful genomic struc- 
ture of  FY, we speculated that its 5‘  region must be compli- 
cated for tissue-specific transcription. Then, we planned to 
reanalyze the transcriptional start position by 5’-rapid ampli- 
fication of cDNA ends (5’-RACE) for the subsequent reeval- 
uation of  the promoter region for organ-specific transcrip- 
tion. 
MATERIALS AND  METHODS 
Normal erythroblasts were obtained from a Duffy- 
positive individual [Fy(a+ b-)]  by  methylcellulose culture in a 35- 
mm non-tissue culture dish (Falcon, Lincoln Park, NJ) as previously 
described.’6 On day  14, erythroid burst-forming unit  (BFU-E)-de- 
rived  red  colonies  were picked  up under  an inverted  microscope 
and were observed by  total RNA extraction using the acid-phenol 
guanidinium method.”  Reticulocyte RNA was isolated from Duffy- 
positive individuals as previously described.’  Human erythroleuke- 
mia  (HEL),  KS62,  KGI, HL60,  KU812, Raj, and MOLT4  cells 
Cell culture. 
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were obtained from the Japanese Cancer Research Resources Bank 
(Tokyo, Japan) and were maintained in RPMI 1640 medium con- 
taining  10% fetal calf  serum (FCS). UT7 cells were provided by 
Dr N. Komatsu (Department of  Hematology, Jichi Medical School, 
Tochigi, Japan) and were maintained in Iscove’s modified Dulbec- 
CO’s  medium (IMDM) containing 10% FCS and 1 ng/mL recombi- 
nant granulocyte-macrophage colony-stimulating factor (GM-CSF; 
Sumitomo Pharmaceutical CO, Osaka, Japan). 
RNA  preparation  from  human  tissues.  Lung,  kidney,  liver, 
spleen, bone marrow (BM), and brain tissues were prepared from a 
54-year-old Japanese  male patient under autopsy, after receiving 
permission for use for research purposes. Total RNA was extracted 
from  I  g of each tissue by  the acid-phenol guanidinium method. 
To determine the complete sequences 
of  the  5’  UTR,  we  performed 5‘-RACE from  the  total RNA  of 
BFU-E-derived  cells  and  lung tissue according to the  procedure 
of  Frohman et all* with  some modifications. An  antisense Duffy 
glycoprotein-specific primer  (ATTCAGGITGACAGGTGGGAA, 
complimentary to nucleotide 1198 to 1218 of Fy71-81 cDNA3)  was 
used to synthesize cDNA. The cDNA was purified by ultrafiltration 
to remove excessive primer and nucleotides, followed by  poly-(A) 
tailing with terminal deoxynucleotidyl-transferase  (Life Technolo- 
gies Inc, Gaithersburg, MD). The poly-(A)-tailed  cDNA was ampli- 
fied  with  a  nested  antisense  primer  (GTGACAGGCAGTGTC- 
AGTAG, complimentary to nucleotide 735 to 716) and an anchor 
primer  (ATCCGTCGACATCGATACGTAA(T)”).  Second nested 
primers (GACATTGGACGACCTACTGA, complimentary to  nu- 
cleotide  340 to  359,  and  ATCCGTCGACATCGATACGT) were 
used in the following polymerase chain reaction (PCR) under strin- 
gent conditions (denaturation at 94°C  for  1  minute, annealing at 
55°C for  1 minute, and  extension at  72°C for  3  minutes, for  35 
cycles). 
To  determine the  complete  sequence of  the  novel  cDNA, we 
performed 3’-RACE. First-strand cDNA was synthesized with the 
anchor primer, and the 5’ end-specific sense primer (TGTCTGCGG- 
GCCTGAACCAA, corresponding to nucleotide -326  to -307)  was 
used in the following PCR. 
The PCR bands were subcloned into pCR I1 vector (Invitrogen, 
San  Diego, CA)  and  sequenced on  both  strands by  the  dideoxy 
termination method.” 
RNA analysis by primer extension and ribonuclease (RNase)  pro- 
tection  assay.  HEL cell poly(A)+ RNA was analyzed using the 
primer extension system according to the instructions of  the manu- 
facturer (Promega, Madison, WI). Poly(A)+ RNA was prepared with 
the PolyATract mRNA Isolation System I11 (Promega). The primers 
(0.1 pmol) specific for the 5’ end of  the novel cDNA (CTGTGC- 
AGAC  AGTTCCCCAT,  complimentary  to  nucleotide  -279  to 
-298)  or  previous  Fy71-81  (TCGGGTGGG AGAACAAGGTC, 
complimentary to nucleotide 89 to 108) were labeled with (y3’P)- 
adenosine triphosphate (ATP) and incubated with  1 pg of  mRNA 
at 57°C for 30 minutes. The reaction products were separated on a 
5% acrylamide gel containing 8 moVL urea and were visualized by 
autoradiography. Two DNA sequencing reactions with each primer 
were used for precise determination of the product length. 
Bone marrow and lung RNA were analyzed by RNase Protection 
Assay Kit (Ambion, TX) according to the instruction manual. The 
5-RACE clone from lung encoding nucleotide -383  to 359 (-279 
to 202 was deleted) and the Fy71-81 clone encoding nucleotide 1 
to  359  were  linearized, and  404-base  and 470-base  radiolabeled 
antisense  RNA  probes were  prepared with  T7  RNA  polymerase 
(MAXIscript; Ambion). Fifty micrograms of  each total RNA was 
hybridized with 20 Kcpm RNA probes at 45°C for  12 hours. The 
hybridized samples were digested with the RNase A/RNase T1 mix- 
RNA analysis by RACE. 
ture at  37°C  for 30 minutes. The products were precipitated and 
subsequently separated on a 5% sequencing gel. 
RNA analysis by Northern blot hybridization.  Fifty micrograms 
per lane of HEL cell, BM, lung, and brain total RNA were separated 
with RNA size markers (Life Technologies Inc) on 12 lanes (three 
lanes per tissue) of a 1.2% formaldehyde/agarose gel and transferred 
to a Hybond-N+ nylon membrane (Amersham Japan, Tokyo, Japan). 
The blot membrane was  separated into three strips for each four 
lanes. The strips were hybridized with respective probes at 65°C; 
specific probe for the novel 5‘ end (complementary to nucleotide 
-326  to -279),  specific probe for the 5’ end of Fy71-81 (comple- 
mentary  to nucleotide  1 to  108), and  a common probe for  open 
reading frame (ORF) of  Duffy glycoprotein (complementary to nu- 
cleotide 579 to 1218). These probes were labeled with (~~-~’P)-deoxy- 
cytidine triphosphate (dCTP) using a random primer  labeling kit 
(Amersham Japan). The blots were washed finally in 0.2X  SSPE 
(lx SSPE  =  150 mmoVL  sodium chloride,  10 mmol/L  sodium 
phosphate, 1 mmoVL sodium EDTA) with 0.1% sodium dodecylsul- 
fate (SDS) at 65°C for 30 minutes and were then exposed to an X- 
ray film with intensifying screen at -80°C  for 72 hours. The devel- 
oped film was analyzed with an image analyzer (Immuno Medica 
Inc, Shizu-oka, Japan). 
One 
microgram of total RNA from reticulocytes, BFU-E-derived  eryth- 
roblasts, and eight leukemic cell lines was reverse-transcribed with 
oligo-d(T)16 and with or without Molony murine leukemia virus- 
reverse transcriptase (M-MLV-RT; Amersham Japan). The cDNAs 
were subsequently amplified (RT-PCR) for 20 cycles with common 
antisense primer (ACTCGAGACTTTAATTCAGGTTGACAGGT, 
complimentary to nucleotide 1203 to  1226 with Xho I linker) and 
specific primer for the novel 5’ end (-326  to -307)  or for the 5’ end 
of Fy71-81 (GGCTTCCCCAGGACTGTTCCTG, corresponding to 
nucleotide  1 to 22). The PCR products were separated on agarose 
gels  and  blotted  on  Hybond-N+  nylon  membranes. The  blotted 
membranes were hybridized with common ORF probe at 65°C for 
12 hours. A final wash was performed at 65°C for 45 minutes in 
0.1X  SSPE with 0.1% SDS. The radioactivity of  the bands were 
measured by  a radioanalytic imaging apparatus (AMBIS Systems 
Inc, San Diego, CA). In  the preliminary study, the amplification 
curves of exon 0.1 and Fy71-81 transcripts were linearly exponential 
and parallel until 27 cycles. 
The full- 
length cDNA with novel 5‘ end was amplified as above from an 
Fy(a-b+)  individual and subcloned in pCR I1 vector, and the insert 
without  misincorporation  was  cloned  into  pcDNAI  vector  (In- 
vitrogen). The K562 cells were transfected with 2 pg of  plasmid 
DNA by  Lipofectamine (Life Technologies Inc) according to the 
manufacturer’s  instructions.  Mock-transfected  K562  cells  were 
transfected with  the  same expression plasmid  lacking the  Duffy 
cDNA. Expression of the Duffy antigen in K562 cells was assayed 
by  staining the cells with MoAb Fy6, which was provided by  Red 
Cross Bloodbank (Osaka, Japan). The cells incubated with Fy6 were 
washed three times and were subsequently incubated with fluorescein 
isothiocyanate-conjugated goat anti-mouse IgG.  After incubation, 
cells were washed three times with phosphate-buffered saline (PBS), 
and fluorescence was measured on a Spectrum 111  flow cytometer 
(Becton Dickinson, Mountain View, CA). 
PCR analysis of  relative expression in hematopoietic cells. 
Construction of  expression plasmid and transfection. 
RES  U  LTS 
Isolation of  a  spliced form of  FY  cDNA.  For  further 
characterization of the 5’ end of Duffy mRNA, we performed 
5’-RACE and isolated seven positive clones from erythro- 
blast RNA and nine clones from lung RNA. All clones en- 
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Fig 1.  Nucleotide  sequence analysis of the 5-RACE clones. (A) The 
5-RACE products from erythroblasts of day-14 BFU-E colonies and 
lung tissue were subcloned into pCR II vector and sequenced with 
universal M13  primer. The thymine stretch at the 5' end indicates 
the poly-(A)  tail at the cDNA terminal. The boundary of exon 0.1 and 
the following sequence shows the splicing position. (E)  The location 
of the spliced-form cDNA in Duffy gene. Exon  sequence is capitalized, 
while the coding sequence of previous unspliced form cDNA is indi- 
cated from nucleotide 1 in lowercase letters. Nucleotide numbers 
correspond to the cDNA sequence deposited in GenBank (accession 
no. U018391 and its genomic structure? ORF sequence is indicated 
by single-letter code below each codon. Bold lowercase letters are 
the terminal dinucleotides for the intron. Arrowheads indicate TSP 
of erythroid determined by primer extension, shown in Fig 2. The 
largest is the major TSP. Overlined and underlined arrows are the 
antisense oligonucleotides used for primer extension. The open trian- 
gle indicates TSP of lung and kidney determined by RNase protection 
study, shown in Fig 3. 
coded a sequence identical to nucleotide 203 to 359 of Fy71- 
81 cDNA, but the following upstream sequences were differ- 
ent (Fig  1A). The sequences of  clones from erythroblasts 
corresponded to the nucleotide from -278  to -3081-357  in 
its genomic structure.'  The clones from lung encoded from 
-278  to -3551-383.  The sequences were regarded as com- 
prising a novel exon, which we temporarily named exon 0.1. 
Exon 0.1  encoded an  ATG codon and, after six residues, 
linked to nucleotide 203 in-frame, in agreement with splicing 
rules. To  determine the  complete sequence of  the cDNA 
initiated with exon 0.1,  we  performed  3-RACE using the 
exon-specific primer and an anchor primer. We isolated four 
positive clones and showed that the spliced form of  Duffy 
cDNA,  which  was  temporarily  designated  FyO.1  clone, 
shared an  identical reading  frame and  a poly  adenylation 
signal with the Fy7 1-8  1 cDNA downstream from nucleotide 
203 (Fig IB). 
Characterization of the transcription start points (TSP)  of 
FY  mRNA  in  erythroid and postcapillary  venule  endothe- 
lium.  To characterize the TSP for FY  gene in  erythroid 
cells without imposing a PCR step bias, poly(A)'  RNA of  a 
human erythroleukemia cell line, HEL, were extended using 
antisense oligo primers corresponding to each 5'  sequence 
and were analyzed in parallel on  the same sequencing gel. 
The  HEL cell  has  been  already shown to express  Duffy 
antigedchemokine  receptor.20 A  reaction  primed  with  an 
oligo nucleotide specific for exon 0.1  identified one major 
and two minor products: 54, 52, and 78 nucleotides, respec- 
tively (Fig 2). Thus, HEL cells, the major TSP lies 34 bp 
upstream from the initiating ATG,  and the main  transcript 
length is estimated at about 1,120 nucleotides. In contrast, 
no obvious banding pattern was obtained with the Fy7 1-8  1 - 
specific oligo. 
To determine the difference in  TSP between hematopoi- 
etic organs and nonhematopoietic  organs, we attempted more 
sensitive RNase protection study. In  bone  marrow RNA, 
the exon 0.1  antisense RNA  probe made a main signal at 
nucleotide 212,  from which  157 (from nucleotide 203 to 
359) and 21 (seven codons in exon 0.1) should be subtracted. 
The resulting position of  34 bases from the first ATG  is 
compatible with the findings on primer extension from HEL 
cells (Fig 3, bold arrow). The lung and kidney revealed two 
signals at nucleotides 262 (open triangle) and 275. The 275- 
base product was estimated as an artifact, because the prod- 
uct length exceeded the protectable probe length. Therefore, 
the major TSP in lung lies 82 bp upstream from the initiating 
ATG, and the main transcript length is estimated at about 
I, 170 nucleotides. On the contrary, Fy7 1-8  1 antisense RNA 
probe showed a single band at 157 nucleotides in all three 
organs (arrowhead), which precisely indicates the estimated 
splicing position (from nucleotide 203 to 359). The unspliced 
form product made a very weak band at nt  359 after pro- 
longed exposure (not shown). 
To deter- 
mine the relative level of expression of the two distinct FY 
mRNAs, three specific probes were used  to three strips of 
Northern blots of HEL cell, BM, lung, and brain RNA. The 
common ORF probe detected  1.2-kb  band  in  all  tissues. 
The exon-0.1-specific probe (48 bp) detected mRNA at an 
identical size (1.2 kb) as did the common probe in all tissues 
(Fig 4). On the contrary, the bands hybridized with the Fy71- 
8  1 mRNA-specific probe (109 bp) were very weak and were 
0.4 kb larger than that of  the exon 0.1 probe. The relative 
intensity of each band was measured with an image analyzer, 
and the ratios of  the exon 0.1-specific band and the Fy71- 
81-specific  band were 1:0.015 in HEL cell and 1:O.W in 
lung.  In  BM  and brain RNA, which seemed to be  highly 
degraded during the postmortem period, the band of Fy71- 
Relative quantijication of the FY  transcripts. 
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8  1 was not obtained. The resolving power of  Northern blot- 
ting was insufficient to distinguish the transcriptional size 
between erythroid and the two organs studied, while from 
TSP analysis, the erythroid transcript is expected to be 48 
nucleotides short compared with lung. The predominance of 
the Fy0.l  transcript was also revealed by  RT-PCR study in 
lung, kidney, liver, spleen, BM, and brain (not shown). 
Distribution of FY 
transcript in hematopoietic cell lines was tested by RT-PCR 
Relative expression of  the FY mRNA. 
78 -+ 
54 -b 
52  -D 
Primer + 
exon 0.1  Fyb71-81 
Fig 2.  Identification of the TSP in  erythroid cells by primer exten- 
sion. The extended products of HEL cell RNA were primed with anti- 
sense oligonucleotides specific for exon 0.1 and Fy71-81 transcripts 
and were separated on the same gel.  In parallel,  DNA  sequencing 
reaction is shown for determination of product length. The gel was 
exposed to X-ray film with intensifying screen at -80%  for 7 days. 
Arrows with numerals indicate  the extended products  with the exon 
0.1-specific primer. The Fy71-81-specific primer did not show any 
positive band. 
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Fig 3.  RNase protection analysis. The antisense RNA probes for 
FyO.l  (404  bases,  arrow) and Fy71-81 transcript 1470 bases) were 
synthesized from linearized plasmid  containing  each cDNA; the Fy0.l 
clone encoded from nucleotide -383  to -279/203  to 359;  the Fy71- 
81 clone encoded from nucleotide 1 to 359.  The RNA probes were 
hybridized  with 50 pg  of BM,  lung, or kidney total RNA and treated 
with RNase TllRNase A;  lane 1  is the product hybridized with Fy0.l 
probe, lane 2 is with Fy71-81 probe. The major protected fragment 
with Fy0.l  probe in BM RNA is indicated by a bold arrow, and the 
fragments in lung and kidney are indicated by the open triangle. 
The  protected fragments with Fy71-81 probe are  indicated by an 
arrowhead. The Fy0.l probes hybridized  with tRNA and treated with 
(+) or without (-1  RNase are shown in the right lanes. The radiola- 
beled RNA size markers are on the left. 
followed by  Southem blot analysis with hybridization to a 
common ORF probe-. The novel spliced-form FY cDNA was 
expressed strongly in reticulocytes, BFU-E-derived  erythro- 
blasts, HEL cells, UT7  cells (megakaryoblastic cell line with 
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Fig 4. 
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Northern blot analvsis. HEL cell, BM. luna. and brain RNA  - 
(50 pg per lane) were separated on 12 lanes (three lanes per sample) 
of a 1.2% denaturing agarose gel and transferred to  a membrane. The 
blot was separated into three strips and hybridized with respective 
probes. Lane  1,  exon 0.1-specific  probe;  lane 2,  common N  ORF 
probe; lane 3, Fy71-81-specific  probe. In every RNA, 1.2-kb transcript 
was observed in both lanes 1 and 2. In HEL  cell and lung, 1.6-kb 
bands were detected in lane 3. The RNA standards are indicated on 
the left. 
erythroid features2'), and KU8 12 cells (premature basophilic 
cell  line with  erythroid features2');  weakly  in  K562 cells 
(erythroleukemic cell line), HL60 cells (promyelocytic cell 
line), and Raji cells (B lymphoid cell line; Fig 5);  and very 
weakly  in  KGl  (myeloblastic cell  line)  and  MOLT4  (T 
lymphoid cell  line) cells,  which expression was detected 
after prolonged exposure (not shown). The Fy71-81 cDNA 
was expressed weakly in reticulocytes, BFU-E, HEL, UT7 
and KU812, but was not detected in W62, HL60, KGI, and 
MOLT4. Without reverse-transcription, no  positive bands 
were detected  in  any  PCR  samples. The radioactivity of 
individual bands was measured by  a radioanalytic imaging 
apparatus and is listed in Fig 5.  The ratio of the FyO. 1 cDNA 
to the Fy71-81 cDNA was 1:0.018 in reticulocytes, 1:0.022 
in BFU-E, 1:0.006 in HEL cells, 1:0.003 in UT-7 cells, and 
1:O.OlO  in  KU812 cells,  respectively. In  other  cells,  the 
Fy7 1-8  1 bands were too weak to estimate the accurate rela- 
tive expression. In general, the results are consistent with the 
predominance of  spliced-form mRNA suggested by primer 
extension, the RNase protection study, and Northern blot- 
ting.  The spliced-form mRNA  was expressed strongly in 
erythroid-committed cells, other than K562 cells. In myeloid 
(KGl, HL60) and lymphoid (Raji, MOLT4) cells, the tran- 
scription of FY  was very weak. 
Suface expression of Dufy product on transfected K562 
cells.  To investigate the influence of  amino terminal modi- 
fication on  antigenicity, the FY  cDNA with  novel 5'-end 
and  Fyb genotype was used  to transfect K562 cells. The 
transfected cells were harvested and stained with Duffy anti- 
gen-specific MoAb Fy6.  Positive staining was obtained on 
the cells transfected with pcDNA-Fyb0.l  (Fig 6). Approxi- 
mately  5%  of  the transfected cells were  stained with  the 
antibody.  No  staining  was  observed  when  cells  were 
transfected with the expression vector alone (mock), or cells 
were stained only with second antibody (Fig 6). In triplicate 
experiments, reproducible results were obtained. 
DISCUSSION 
We have previously shown that the Duffy gene was con- 
structed in a single exon, and its predicted promoter sequence 
was highly  pyrimidine-rich'  (82%), in  contrast with most 
eukaryotic promoters, which are GC-rich or include TATA 
and CCAAT boxes. To reanalyze the TSP of FY  in erythroid 
cells and to discover the TSP of postcapillary venule endo- 
thelium, we performed 5'-RACE and isolated a novel Fy0.l 
cDNA that was distinct from the Fy7 1-8  1 clone of Chaudhuri 
et a13 at its 5' end. We have not yet been able to isolate an 
identical clone to Fy71-81 using this procedure. The 5'  end 
of  the novel cDNA was located at  -278  bases upstream 
from the TSP of Fy71-81 and was identified as exon 0.1. 
The exon 0.1  encodes seven residues that are initiated with 
a methionine and connect with nucleotide 203 in-frame and 
in  accordance with  the  GT-AG  splicing rule.  The Fy0.l 
cDNA is regarded as a splicing isoform. A major erythroid 
TSP was identified by  primer extension analysis with HEL 
cell RNA  at 34 bp upstream from the first ATG. The TSP 
was confirmed by  RNase protection assay with BM  RNA. 
In  lung and kidney RNA, the transcription started at 82 bp 
upstream from the ATG. Then, instead of the nine N-terminal 
residues of  the Fy71-81 cDNA product, seven residues of 
the FyO.1  cDNA are predicted to be a signal sequence for 
the initial membrane penetration into endoplasmic reticulum. 
The upstream sequence of  the  novel  initial  ATG  is  also 
lacking TATA or CCAAT boxes, but  includes short GC 
stretches. 
Northern blotting and RT-PCR followed by Southern blot- 
ting clearly showed the predominant expression of the FyO. 1 
transcript in erythroid cells and in every organ studied. The 
predominance  of  the  spliced-form transcript  in  erythroid 
cells is consistent with the absence of  an  obvious band in 
primer  extension  analysis  primed  with  Fy71-81 -specific 
oligo and with the unsuccessful cloning of Fy71-81 cDNA 
by  5'-RACE.  Furthermore, dominance was  also revealed 
by  RNase protection assay. The Fy71-81 probe showed the 
splicing position mainly and exactly. Therefore, it is obvious 
that the Fy0.l  transcript is the main  transcript in both ery- 
throid and postcapillary venule endothelium. 
Recently, Toumamille et aIz3  identified a novel  cap site 
in the Duffy gene at 484 nucleotides upstream from the first 
ATG identified by Chaudhuri et a13 using 5'-RACE and the 
primer extension procedure. Their TSP is similar to our data 
in erythroid cells. However, a first ATG appears at the same 
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Fig 5.  Relative quantification of the Ntranscripts 
in hematopoietic cells by RT-PCR with Southern blot- 
ting. Total RNA (1 pg) extracted from reticulocytes 
(Ret),  BFU-E cells.  and HEL,  K562,  Ul7, KG1,  HL60, 
KU812, Raji, and MOLT4 cells was converted to  cDNA 
by reverse transcription and subjected  to 20 cycles of 
PCR. The PCR products  were electrophoresed  through 
two 1.2% agarose gels, transferred to a nylon mem- 
brane, and hybridized with common N  ORF probe. 
In each cell line, lane 1 is the PCR products with exon 
0.1-specific primer, lane 2 is the products with Fy71- 
81 primer, and lane 3 is the products with Fy71-81 
primer without reverse-transcriptase.  Arrowheads at 
a and b indicate the 1,231-bp Fy71-81 cDNA bands 
and the 1,078-bp Fy0.l cDNA bands, respectively.  The 
radioactivities of  a  and b bands were measured in 
each cell line and are listed below the figure. 
123 123 123 123 123 123 123 123 123 123 
Ret  BNe  HEL  K562  UT7  KG1  HL60 KU812  Raji  MOLT4  ---------- 
acpm  730  9~)  327  -  146  -  *  569  ' 
(SD)  +42  +45  a28  a18  t38 
bcpm  40552 44486 50662  128 57066  .  33  57073  46  * 
(SDI  a317  i331  t354  i19  t436  t14  i329  i-17 
not slgniftcant than 0 
2.32 
2  02 
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position as the Fy0.l  cDNA in their proposed long 5'  non- 
coding region, and several termination codons emerge in the 
following intronic sequence. Thus, their cDNA seems to be 
the prespliced hnRNA. It was difficult to rule out the possi- 
bility  that  our  RT-PCR  products from Fy7 1-8  1  transcript 
were amplified from the hnRNA. The difference in the tran- 
scriptional size (0.4 kb) between FyO.1  and Fy71-81, which 
was suggested by Northern blotting, supports this possibility. 
The presence of multiple transcription initiation sites and 
tissue-specific promoters involved in tissue-specific gene ex- 
pression have been reported for a growing number of other 
genes, such as band  3,24  band 4.1,"  glycophorin C,'* and 
glucocorticoid re~eptor.~'  Duffy gene transcripts have been 
shown to be widely distributed in many  organs, including 
lung, muscle, spleen, heart, pancreas, kidney, and 
Postcapillary venule endothelium is the cell that expresses 
the Duffy blood group antigen in these organs." We showed 
that the spliced transcript was also the predominant transcript 
in those organs with a difference in TSP from erythroid cells. 
The TSP in lung and kidney was 48 bases upstream from that 
of the erythroid cell. The postcapillary venule endothelium- 
specific promoter must exist in  the upstream. In  addition, 
fetal brain has been shown to transcribe remarkably larger 
RNA  compared with other organs and adult brain?  In  the 
brain, Duffy gene should be transcribed in a time- and organ- 
specific manner. The manner in  which the respective pro- 
moter initiates the respective transcription start sites must 
be determined in the future. 
In  RT-PCR analysis, the strong signal was observed re- 
strictedly in erythroid-committed cells among eight leukemic 
cell  lines. The Fy(a-b-)  individuals do not  produce  FY 
mRNA in the BM,.' in accordance with the absence of  Duffy 
glycoprotein on their erythrocytes. However, Chaudhuri et 
a14 showed that lung, spleen, colon, and kidney of  Duffy- 
negative individuals produce mRNA  of  the same size but 
in  less quantity than  those of  Duffy-positive individuals. 
Moreover, Peiper et a126 showed the expression of  Duffy 
glycoprotein in endothelial cells of  Fy(a-b-)  individuals. 
Toumamille et a12'  showed that a T-to-C substitution at 46 
bases upstream from their proposed cap site, which we also 
found in three Duffy-negative, black  individuals living in 
Japan,  abolished erythroid expression. The  mutation  dis- 
rupted the inverted consensus binding site for the GATA 
transcription  factor  (double  underscore  in  Fig  IB).  The 
GATA motif is positioned downstream from the TSP of lung 
and kidney and 30 bp upstream from the TSP of erythroid 
cells. This GATA motif should play the core role for the 
promoter in erythroid cells but will not be essential to tran- 
scribe FY gene in postcapillary venule endothelium. If  the 
endothelial cell  lines expressing the  Duffy  product  were 
available, this subject should be resolved. 
The recombinant Fy7 1-8 1  was transfected and success- 
fully expressed on K562 cells' and human embryonic kidney 
cell line 293.9 The expressed proteins reacted with  Duffy 
glycoprotein-specific murine MoAbs Fy6 and Fy3. We also 
showed that the Fy0.l  cDNA products expressed on K562 
cells successfully reacted with MoAb Fy6. This fact indicates 
that the substitution of  nine residues in Fy71-81 with the 
novel seven residues of FyO. 1 does not influence the epitope 
for Fy6 and the proper embedding of the glycoprotein into 
the plasma membrane. Therefore, we conclude that the prod- 
uct from spliced-form FY mRNA is the main product of red 
blood cells. 
From  the  comparison  of  the  deduced  amino  acid  se- 
quences of humans and simians, Chaudhuri et a14 proposed 
the recognition site of Fy6 to be  the residue 22-40,  not 
the N-terminus. Our expression study supports this specula- 
tion. We are now processing the binding study of the FybO. 1 
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Fig 6.  Construction of  expression plasmid and transfection.  (A) 
Schematic illustration of the expression vector. (B) Flow cytometric 
analysis of K562 cells transfected with the vectors. Resuks are ex- 
pressed as histograms  of cell number on the ordinate versus fluores- 
cence intensity (log scale) on the abscissa. The solid line indicates 
the histogram of K562 cells incubated with Fy6 MoAb and with a 
second fluorescein isothiocyanate-labeled antimouse antibody. The 
dashed line shows fluorescence of  K562 cells incubated with only 
the  second  antibody  as  a  negative  control.  Mock  cells  were 
transfected  with the same expression vector lacking the Duffy cDNA. 
clone product and promiscuous chemokines to determine the 
influence of the N-terminal substitution on the ligand bind- 
ing. The dissociation constant value for IL-8 binding to K562 
or 293 cells transfected with Fyb71-81 cDNA was slightly 
higher than those values for erythrocytes and HEL cells.8~y~’y 
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